- Home
- ADAP vs SKIL Comparison
ADAP vs SKIL Comparison
Compare ADAP & SKIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- SKIL
- Stock Information
- Founded
- ADAP 2008
- SKIL 1998
- Country
- ADAP United Kingdom
- SKIL United States
- Employees
- ADAP N/A
- SKIL 2318
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- SKIL Computer Software: Prepackaged Software
- Sector
- ADAP Health Care
- SKIL Technology
- Exchange
- ADAP Nasdaq
- SKIL Nasdaq
- Market Cap
- ADAP 158.6M
- SKIL 260.6M
- IPO Year
- ADAP 2015
- SKIL N/A
- Fundamental
- Price
- ADAP $0.58
- SKIL $31.46
- Analyst Decision
- ADAP Strong Buy
- SKIL Buy
- Analyst Count
- ADAP 4
- SKIL 3
- Target Price
- ADAP $2.79
- SKIL $35.00
- AVG Volume (30 Days)
- ADAP 2.3M
- SKIL 63.5K
- Earning Date
- ADAP 03-05-2025
- SKIL 12-10-2024
- Dividend Yield
- ADAP N/A
- SKIL N/A
- EPS Growth
- ADAP N/A
- SKIL N/A
- EPS
- ADAP N/A
- SKIL N/A
- Revenue
- ADAP $175,041,000.00
- SKIL $534,780,999.00
- Revenue This Year
- ADAP $204.91
- SKIL N/A
- Revenue Next Year
- ADAP N/A
- SKIL $5.19
- P/E Ratio
- ADAP N/A
- SKIL N/A
- Revenue Growth
- ADAP 146.27
- SKIL N/A
- 52 Week Low
- ADAP $0.53
- SKIL $5.09
- 52 Week High
- ADAP $2.05
- SKIL $32.00
- Technical
- Relative Strength Index (RSI)
- ADAP 41.87
- SKIL 88.87
- Support Level
- ADAP $0.55
- SKIL $28.99
- Resistance Level
- ADAP $0.65
- SKIL $32.00
- Average True Range (ATR)
- ADAP 0.05
- SKIL 2.36
- MACD
- ADAP 0.00
- SKIL 0.49
- Stochastic Oscillator
- ADAP 31.31
- SKIL 95.94
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segment includes Content & Platform and Instructor-Led Training. The Content & Platform business engages in the sale, marketing and delivery of its content learning solutions, in areas such as Leadership and Business, Technology and Developer and Compliance. The Instructor-Led Training business offers training solutions covering information technology and business skills for corporations and their employees. The majority of revenue is from the Content & Platform segment.